T cell exclusion, immune privilege,and the tumor microenvironment

T cell exclusion, immune privilege,and the tumor microenvironment

T cell exclusion, immune privilege,and the tumor microenvironment

CANCERIMMUNOLOGYANDIMMUNOTHERAPY

9.N.H.Segaletal.,CancerRes.68,889–892(2008).10.J.C.Castleetal.,CancerRes.72,1081–1091(2012).11.H.Matsushitaetal.,Nature482,400–404(2012).12.P.F.Robbinsetal.,Nat.Med.19,747–752(2013).13.N.vanRooijetal.,J.Clin.Oncol.31,e439–e442(2013).

14.F.Duanetal.,J.Exp.Med.211,2231–2248(2014).15.M.M.Gubinetal.,Nature515,577–581(2014).16.C.Linnemannetal.,Nat.Med.21,81–85(2015).

17.Y.C.Luetal.,Clin.CancerRes.20,3401–3410(2014).18.E.Tranetal.,Science344,641–645(2014).

19.D.A.Wicketal.,Clin.CancerRes.20,1125–1134(2014).

20.M.Yadavetal.,Nature515,572–576(2014).21.M.Rajasagietal.,Blood124,453–462(2014).22.N.A.Rizvietal.,Science348,124–128(2015).

23.M.Gerlingeretal.,N.Engl.J.Med.366,883–892(2012).

24.M.M.vanBuuren,J.J.Calis,T.N.Schumacher,OncoImmunology3,e28836(2014).

25.M.H.Fortieretal.,J.Exp.Med.205,595–610(2008).26.E.F.Fritschetal.,CancerImmunolRes2,522–529(2014).

27.C.A.VanBergenetal.,CancerRes.70,9073–9083(2010).

28.J.J.A.Calisetal.,PLOSComput.Biol.9,e1003266(2013).29.M.E.Dudley,D.C.Roopenian,J.Exp.Med.184,441–447(1996).

30.T.Wölfeletal.,Science269,1281–1284(1995).31.T.Schumacheretal.,Nature512,324–327(2014).

32.C.M.Koebeletal.,Nature450,903–907(2007).numerouscelltypesinadditiontocancerthecancer.Immunoediting,ortheeliminationcells,whichincludebonemarrow–derivedofimmunogeniccancercells(7),couldbeex-inflammatorycells,lymphocytes,bloodves-cluded,whichleftthepossibilityofimmunesup-sels,fibroblasticcells,andtheextracellularpressionbythetumormicroenvironment(TME).matrixcomposedofcollagenandproteoglycansDespitethisevidencethatthepresenceofantigen-(1,2).Theimportanceofastromalmicroenvi-specificCD8+Tcellsalonemaynotbesufficient33.V.Shankaranetal.,Nature410,1107–1111(2001).ronment,especiallyonethathascharacteristicsofforthecontrolofcancer,amajorpharmaceutical34.M.DuPage,C.Mazumdar,L.M.Schmidt,A.F.Cheung,T.Jacks,Nature482,405–409(2012).

a“wound”orregeneratingtissue,hasbeenrec-companyrecentlyconductedphaseIIItrialsin35.M.S.Rooney,S.A.Shukla,C.J.Wu,G.Getz,N.Hacohen,Cellognizedforatleastacentury(3),butitspossiblepatientswithnon–smallcelllungcancer(NSCLC)160,48–61(2015).

roleinbluntinganimmuneattackofcancercellsoftheclinicalefficacyofvaccinationwiththe36.P.Kvistborgetal.,Sci.Transl.Med.6,254ra128(2014).37.P.Kvistborgetal.,OncoImmunology1,409–418awaitedthediscoveryofadaptivecellularim-MAGE-A3antigen(MAGRIT,NCT00480025).The(2012).

munity.In1960,Kleinandcolleaguesfoundthatstudydidnotmeetitsprimaryendpointofex-38.S.D.Brownetal.,GenomeRes.24,743–750(2014).whenmicedevelopedprimarymethylcholanthrene-tendingdisease-freesurvivalandwasdiscontinued39.A.Snyderetal.,N.Engl.J.Med.371,2189–2199inducedsarcomas,theyalsodevelopedananti-in2014.Moreover,Rosenbergandcolleaguesre-(2014).

40.T.N.Schumacher,C.Kesmir,M.M.vanBuuren,CancerCell27,tumorimmuneresponsemediatedbylymphportedevidenceofdiseaserecurrenceinmela-12–14(2015).

nodecellstoasecondarychallengecomprisingnomapatientsdespiteveryhighlevelsofvaccine-41.D.S.Chen,I.Mellman,Immunity39,1–10(2013).

cancercellsderivedfromtheprimarytumorinducedcirculatingTcellsandnoevidenceof42.C.M.Cabreraetal.,TissueAntigens61,211–219(2003).(4).Theparadoxicalandcriticalfindingoftheantigenlossbythecancercells(8).

43.L.A.Johnsonetal.,Blood114,535–546(2009).

44.N.N.Hunderetal.,N.Engl.J.Med.358,2698–2703studywasthatthisanticancerimmuneresponseThediscoveryofmelanoma-specificTcellsin(2008).

didnotcontrolthegrowthoftheprimarytumor,patientsledtoanotherstrategytoincreasethe45.P.F.Robbinsetal.,Clin.CancerRes.21,1019–1027despiteitsabilitytopreventtheestablishmentfrequencyofcancer-specificTcellsinpatients,(2015).

ofasecondarytumorcomprisingcancercellsthatofadoptivelytransferringlargenumbers46.V.Boisguérinetal.,Br.J.Cancer111,1469–1475(2014).

derivedfromtheprimarytumor.Intraditionalofinvitroexpandedtumor-infiltratinglympho-47.E.F.Fritsch,N.Hacohen,C.J.Wu,OncoImmunology3,immunologicalterminology,theprimarytumorcytes(TILs).Asdiscussedelsewhereinthisissuee29311(2014).

evadedimmunecontrolbyestablishinganofScience(9),thisapproachhasshownsome48.R.H.Vonderheide,K.L.Nathanson,Nat.Med.19,immune-privilegedmicroenvironmentthatisefficacy,whichhasbeenofmajorimportanceto1098–1100(2013).

functionallyanalogoustothatofcertainnormalthefieldbyservingasproofthattheimmunesys-49.C.G.Josephetal.,Science343,152–157(2014).

50.L.B.Alexandrovetal.,Nature500,415–421(2013).tissues,suchastheeye(5).

temhasthepotentialtocontrolcancer(10).How-51.S.A.Forbesetal.,NucleicAcidsRes.43,D805–D811Unambiguousevidencefortheinabilityinever,adoptiveTcelltherapy(ACT)withTILshas(2015).

humansofasystemicimmuneresponsetoelimi-nothadthedramaticsuccessofACTwithvirus-52.P.A.Futrealetal.,NatureRev.Cancer4,177(2004).

nateimmunogeniccancercellswasprovidedbyspecificCD8+Tcellstoimmunodeficientbonemar-ACKNOWLEDGMENTS

Boon’sstudies30yearslateroftheantigensthatrowtransplantrecipientswithcytomegalovirusThisworkissupportedbyWorldwideCancerResearchelicitspecificCD8+Tcellresponsesinmelanomainfection(11)orEpstein-Barrvirus–associatedlym-grant14-0321,DutchCancerSocietygrantNKI2012-5463,patients(6).ClonedCD8+Tcellsfromamela-phoproliferativedisorders(12).DifferencesinthetheDutchCancerSocietyQueenWilhelminaAward,theStandnomapatientwereusedtoidentifytheantigenmicroenvironmentsofvirallyinfectedtissuesandUpToCancer–CancerResearchInstituteCancerImmunologyTranslationalCancerResearchGrant(toT.N.S.),theNationalexpressedbythatpatient’scancer:MAGE-A1.Thecancersmayaccountforthesedistinctoutcomes,CancerInstitute(RO1CA04305926),theCancerResearch

explicitdemonstrationofthecoexistenceofapro-withthelatterbeingimmune-suppressive.AnotherInstitute,theWWWWFoundation,andtheCancerFrontierFundgressingmelanomawithmelanoma-specificTcellsimportantpointofcomparisonisthattheTMEoffromTheSitemanCancerCenter/Barnes-JewishHospitalinthispatientimplicitlyraisedthequestionof

solidcancersislikelytobefundamentallydifferent(toR.D.S.).SU2CisaprogramoftheEntertainmentIndustryFoundationadministeredbytheAmericanAssociationforCancertothatoftheleukemias,inwhichclinicaltrialsofResearch.WethankJ.Haanen,M.vanBuuren,andP.Kvistborg1

CancerBiologyandGeneticsProgram,MemorialSloanACTwithTcellsexpressingchimericantigenre-forvaluablediscussions.T.N.S.hasanpaidadvisoryrelationshipKetteringCancerCenter,NewYork,NY10065,USA.2Coldceptors,so-calledCARTcells,havedemonstrablewithThirdRockVenturesandKitePharma.R.D.S.hasapaidSpringHarborLaboratory,NewYork,NY11724,USA.efficacy(9).ThesefindingsraisethepossibilityadvisoryrelationshipwithThirdRockVenturesandJounce3

DepartmentofMicrobiologyandImmunology,JoanandTherapeutics.

SanfordI.WeillDepartmentofMedicine,WeillCornellMedicalthatincreasingthefrequencyofcancer-specificSchool,NewYork,NY10065,USA.

Tcells,bywhatevermeans,maybemoreeffective*Correspondingauthor.E-mail:joycej@http://www.1mpi.com(J.A.J.);ifcombinedwithanapproachthataltersthe10.1126/science.aaa4971

T cell exclusion, immune privilege,and the tumor microenvironment

dfearon@cshl.edu(D.T.F.)

immune-suppressiveTME.

74

3APRIL2015 VOL348ISSUE6230

http://www.1mpi.comSCIENCE

Downloaded from http://www.1mpi.com on April 3, 2015

T cell exclusion, immune privilege,and the tumor microenvironment相关文档

最新文档

返回顶部